Summary
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
History
Founded in 2015 by Flagship Pioneering, Wave Life Sciences was established on the premise that directed evolution in the lab and the use of powerful algorithms could improve the existing chemistry that enables targeted delivery of medicines or diagnostics inside the body.
Mission
Wave Life Science's mission is to create medicines that are effective, controllable, and deliver long-lasting benefits for patients with genetic, immune and other diseases.
Vision
Wave Life Science's vision is to create a world where every patient is treated with a precision medicine, regardless of their access to insurance or state of their economic status.
Key Team
Mr. Jonathan Rosin (Chief HR Officer)
Dr. Sridhar Vaddeboina Ph.D. (Sr. VP of Chemistry, Manufacturing & Controls)
Dr. Stephen L. Lake (Sr. VP & Head of Clinical Devel.)
Ms. Anne-Marie Li-Kwai-Cheung (Chief Devel. Officer)
Kate Rausch (Head of Investor Relations)
Ms. Linda Rockett J.D. (Gen. Counsel)
Dr. Christopher Francis Ph.D. (Sr. VP of Corp. Devel. & Head of Emerging Areas)
Recognition and Awards
In 2020, Wave Life Sciences was awarded the Golden Star Award from the International Society for Cellular Therapy in recognition of its pioneering work in developing revolutionary therapies and treatments.
References
Singapore 